WELCOME TO The PHARMACEUTICAL REPORT
Newsletter | Member Login | Signup
Home > Companies > Merck KGaA, Darmstadt, Germany
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Merck KGaA, Darmstadt, Germany | January 09, 2017
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, and The University of Texas MD Anderson Cancer Center today announced a three-year strategic collaboration, with the aim of more quickly advancing the development of investigational cancer therapies in four cancers – breast, colorectal, glioblastoma and leukemia....
Merck KGaA, Darmstadt, Germany | January 11, 2017
Merck KGaA, Darmstadt, Germany, a leading science and technology company which operates its biopharmaceutical business in the US and Canada as EMD Serono, today announced that it has entered into a licensing agreement with Vertex Pharmaceuticals Incorporated, Boston, USA, for the worldwide development and commercialization of four promising research and development programs that represent novel approaches to the treatment of cancer....
Merck KGaA, Darmstadt, Germany | January 23, 2017
Merck KGaA, Darmstadt, Germany, a leading science and technology company which operates its biopharmaceutical business in the US and Canada as EMD Serono, today announced it has entered into a collaboration and licensing agreement with Domain Therapeutics, Strasbourg, France, to explore the potential of adenosine inhibition in the development of novel immuno-oncology agents. This collaboration strengthens our combination strategy in immuno-oncology, and underscores Merck KGaA, Darmstadt, Germany...
Business Insights
Biocytogen and Merck KGaA, Darmstadt, Germany | August 26, 2022
Biocytogen Pharmaceuticals Co., Ltd. entered into a global licensing agreement with Merck KGaA, Darmstadt, Germany, for the use of Biocytogen’s RenMiceTM platform. Under the terms of the agreement, Merck KGaA, Darmstadt, Germany will have full access to Biocytogen’s RenMiceTM platform to discover and develop fully human antibody therapeutics for an unlimited number of drug targets. Merck KGaA, Darmstadt, Germany will be responsible for all clinical development, manufacturing, and com...
Article
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE